BioWorld MedTech

Sep. 13, 2016

Alere, Abbott agree to mediation, not much else in contested merger nuptials

A court battle between Alere Inc. and its potential acquirer Abbott Labs could be inching towards a resolution. The two sides agreed last week to work with a mediator to resolve the dispute, which has landed in the Delaware Chancery Court. Read More

Sanofi, Verily Life Sciences invest $500M for their Onduo diabetes-focused collaboration

BSX's Craig Thompson shares perspectives on the interventional cardiology market

Mylan has invested $1B to raise awareness of need for Epipen

Attorney says FDA faces losing court battles over tissue therapy regulation

Other news to note

Appointments and advancements

Financings

Product briefs

MDD's Cardiology Extra

Today's news in brief

BioWorld

BioWorld briefs for May 22, 2026.

Acid alpha-glucosidase molecular structure isolated on black

‘Detargeted’ targeted gene therapy improves activity in Pompe

BioWorld

A new strategy aims to improve gene therapy for Pompe disease by optimizing both the genetic component that restores the function of a deficient lysosomal enzyme...

Sangamo presents primate data for prion suppressor ST-506

BioWorld Science

Sangamo Therapeutics Inc. discussed gene regulation approaches for neurodegenerative diseases when presenting findings on their clinical candidate ST-506 for the...

TREM2 agonists detailed in Pfizer patent

BioWorld Science

Pfizer Inc. has reported new triggering receptor expressed on myeloid cells 2 (TREM2) agonists potentially useful for the treatment of neurodegeneration.

Roche reports new TREM2 agonists

BioWorld Science

F. Hoffmann-la Roche Ltd. and Hoffmann-La Roche Inc. have identified new triggering receptor expressed on myeloid cells 2 (TREM2) agonists potentially useful for...